Liquid biopsy researchers to share their strategies for pairing digital PCR and next-generation sequencing at Precision Medicine World Conference
HERCULES, Calif. — January 23, 2017 — Global leaders in cancer research and clinical care will discuss how they combine next-generation sequencing (NGS) and Droplet Digital™ PCR (ddPCR™) technologies to analyze cancer liquid biopsies in a specially themed session at the Precision Medicine World Conference (PMWC) in Silicon Valley, CA, January 23-25.
"The choice of technology to analyze liquid biopsies in cancer depends on many factors," said George Karlin-Neumann, PhD, session chair and Director of Scientific Affairs at Bio-Rad's Digital Biology Group. "NGS offers the ability to profile biomarkers broadly while focused quantitative measurements are enabled by digital PCR technology."
NGS and ddPCR are rapidly becoming known as technologies at the forefront of liquid biopsy genetic testing. In situations where a large number of genetic abnormalities may be the cause of a disease, NGS analysis provides a comprehensive snapshot of the many possible mutations. ddPCR is a more targeted mutational analysis tool delivering speed, reproducibility, and high sensitivity. In cancers that can be diagnosed (or tracked) using a limited number of mutated markers, using ddPCR to analyze liquid biopsies provides fast and precise answers. Speakers in the session "Complementary Use of Digital PCR and NGS in Cancer Liquid Biopsy" will discuss important factors when selecting either NGS or ddPCR technology, including cancer type and stage, urgency of need for the information, what is already known, and what can be usefully learned about a specific patient's disease.
This session will be held 10:30-11:30 AM on Wednesday, January 25 as part of Track 1. Please find further details on the presentations below.
Directing First-Line Lung Cancer Treatment
Lauren Ritterhouse, MD, PhD, molecular genetic pathology fellow at Brigham and Women's Hospital and Harvard Medical School in Boston, will report on a clinical liquid biopsy that delivers results for the initial plasma test in four days, which is at least one week shorter than traditional invasive biopsies.
"A fast turnaround time enables the oncologist to be more expedient in selecting an appropriate first-line therapy for the patient, or in changing therapies for a patient who has developed resistance," said Ritterhouse. "The ability to obtain quick results also means that we can use this assay to serially monitor a patient's response to targeted therapy."
Using ddPCR technology on plasma samples, Ritterhouse's team can detect EGFR hotspot mutations with a sensitivity of 72-92% and a specificity of 100%, compared to traditional tissue genotyping methods. Her team performs a targeted NGS panel on the tissue specimens to look for other driver mutations only if ddPCR testing finds EGFR to be wild-type in the plasma as well as in the tissue specimen.
Overcoming Tumor Heterogeneity to Detect Metastasis
Tumor heterogeneity significantly hampers the ability to monitor cancer progression and develop companion diagnostics. One method to overcome this challenge to detecting occult metastases is to use ddPCR technology to track chromosomal rearrangements. Lao Saal, MD, PhD, assistant professor and head of the translational oncogenomics unit at Lund University in Lund, Sweden, and founder of SAGA Diagnostics, will present results using this approach. Specifically, NGS of primary tumors enumerates tumor-specific chromosomal rearrangements. These rearrangements are then used to design personalized ddPCR assays for follow-up testing of a patient's plasma.
Saal will also discuss the clinical potential of ultrasensitive and ultraspecific detection methods to quantify cancer gene mutations for targeted cancer therapy.
"Rapid, noninvasive molecular diagnostics, including digital PCR-based approaches such as our KROMA method for residual disease and IBSAFE for mutation analysis, will be an important aspect of precision oncology going forward," said Saal.
Preempting Breast Cancer Relapse
Isaac Garcia-Murillas, PhD, senior scientific officer at the Institute of Cancer Research in London, will present a novel approach to identifying risk of relapse among patients with early-stage breast cancer using NGS and ddPCR. Mutations identified in tumor DNA by NGS can subsequently be tracked noninvasively by measuring circulating tumor DNA in patients' plasma using ddPCR. The results of Garcia-Murillas' recent study showed that NGS and mutation-specific ddPCR analysis had a high level of agreement on quantities of baseline tumor DNA when assessing the mutant allele fractions, demonstrating the ability to develop robust ddPCR assays for diverse mutations.
"Mutation tracking and massive parallel sequencing analysis of circulating tumor DNA could help define the genetic events of minimal residual disease, therefore allowing for earlier identification of patients with breast cancer at high risk of relapse," said Garcia-Murillas.
Knowing this risk, physicians could potentially tailor adjuvant therapies to decrease the chances of cancer relapse.
More information about this session is available at pmwcintl.com/2017sv/sessionthemes-digitalpcr/.
The QX200 Droplet Digital PCR System is currently for research use only.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs over 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit http://www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce products to the molecular diagnostics testing market and our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.